GALAPAGOS – Hiccups due to EULAR ’13 – GLPG0634 data manageable, Maturing Pipeline + Partnerships of Novel Targets opportunity remains!

Date: 2015-07
Pages:5
Price:

Galapagos (GLPG) presented detailed PhIIa data at EULAR ’13 (Abstract # THU0229) of GLPG0634 (PhII, a selective JAK1 inhibitor, partnered with Abbott for RA) at 4 weeks which differed from the previously presented PoC 4-week data at ACR ’12 – 2489 (Table 1). While this did raise doubts on the robustness of the efficacy, the safety looks best-in-class amongst all JAKs / oral drugs in RA with other doses. Based on our discussion with the management there is still not any clear reason for the discrepancy of the efficacy data seen in the 150mg and 300mg arms and only long term study data will succeed in removing these doubts. However, we believe key differences to note in these trials are… For more details, please read our report released on June 24, 2013, titled, “Hiccups due to EULAR ’13 – GLPG0634 data manageable, Maturing Pipeline + Partnerships of Novel Targets opportunity remains!”

Contact With Us
Join templatemonster at google+
Customized Research
Request Sample